Eugenics Lurk in the Shadow of CRISPR
By Robert Pollack,
Science
| 05. 22. 2015
Untitled Document
In calling their perspective “A prudent path forward for genomic engineering and germline gene modification” (3 April, p. 36; published online 19 March), D. Baltimore et al. show at once the size of the problem and the modesty of their response to it. CRISPR-Cas9, invented by the ninth author, Jennifer Doudna, allows the alteration of specific DNA in the mammalian genome. The authors say that “CRISPR-Cas9 technology, as well as other genome engineering methods, can be used to change the DNA in the nuclei of reproductive cells that transmit information from one generation to the next (an organism’s ‘germ line’).” This is a big deal. It means that we can imagine a day when human chromosomes may be modified in the sperm and egg to assure that one or another aspect of a child’s inheritance is designed to order.
This is a huge departure from current understanding, but the authors are remarkably circumspect. They call for the convening of a “globally representative group of developers and users of genome engineering technology and experts in genetics, law, and bioethics...
Related Articles
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...
By Jason Kehe, Wired | 04.11.2024
God help the babies! Or, absent God, a fertility startup called Orchid. It offers prospective parents a fantastical choice: Have a regular baby or have an Orchid baby. A regular baby might grow up and get cancer. Or be born...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...